Dow Up1.14% Nasdaq Up0.12%

DepoMed Inc. (DEPO)

-NasdaqGS
15.34 Up 0.04(0.26%) 3:21PM EDT - Nasdaq Real Time Price
ProfileGet Profile for:
DepoMed Inc.
7999 Gateway Boulevard
Suite 300
Newark, CA 94560
United States - Map
Phone: 510-744-8000
Fax: 510-744-8001
Website: http://www.depomedinc.com

Details 
Index Membership:N/A
Sector:Healthcare
Industry:Drug Manufacturers - Other
Full Time Employees:291

Business Summary 

Depomed, Inc., a specialty pharmaceutical company, develops products for pain and other conditions, and diseases of the central nervous system in the United States. It offers Gralise (gabapentin), an once-daily product for the management of postherpetic neuralgia; Zipsor (diclofenac potassium) liquid filled capsule, a non-steroidal anti-inflammatory drug for the treatment of mild to moderate acute pain in adults; CAMBIA (diclofenac potassium for oral solution), a non-steroidal anti-inflammatory drug indicated for acute treatment of migraine attacks in adults; and Lazanda (fentanyl) Nasal Spray, an intranasal fentanyl drug used to manage breakthrough pain in adults. The company is also involved in the clinical development of DM-1992 that completed a Phase II trial for Parkinson's disease. Depomed, Inc. sells its Gralise products to wholesalers and retail pharmacies. It has license and collaboration agreements with Abbott Products Inc.; Santarus, Inc.; Boehringer Ingelheim International GMBH; Ironwood Pharmaceuticals, Inc.; Janssen Pharmaceutica N.V.; Janssen Pharmaceuticals, Inc.; Mallinckrodt; Patheon Puerto Rico, Inc.; and Valeant Pharmaceuticals International, Inc. The company was founded in 1995 and is headquartered in Newark, California.

Key Statistics


Company Websites 
Home Page
Search Yahoo! for:
More on DepoMed Inc.

Corporate Governance 
DepoMed Inc.’s ISS Governance QuickScore as of Oct 1, 2014 is 7. The pillar scores are Audit: 1; Board: 6; Shareholder Rights: 7; Compensation: 6.
Brought to you by Institutional Shareholder Services (ISS)

Key Executives 
 PayExercised
Mr. James A. Schoeneck , 56
Chief Exec. Officer, Pres and Director
1.03M0.00
Mr. August J. Moretti J.D., Esq., 63
Chief Financial Officer, Principal Accounting Officer and Sr. VP
518.00K0.00
Mr. Matthew M. Gosling , 43
Sr. VP and Gen. Counsel
544.00K0.00
Mr. Thadd M. Vargas , 48
Sr. VP of Bus. Devel.
472.00K35.00K
Mr. Julian N. Stern , 89
Sec.
18.00KN/A
Amounts are as of Dec 31, 2013 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc.Exercised is the value of options exercised during the fiscal year.
Currency in USD.
View Insiders